May 29, 2026
Friday, May 29, 2026
Today: 8 trending tweets, 8 new studies.
New Research
Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.
Digestive diseases and sciences
After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care.
Journal of medical Internet research
Semaglutide Inhibits Osteoblast Ferroptosis Induced by Diabetic Periodontitis via Modulating the Wnt5a/Ror2/p38 MAPK Signaling Pathway.
Drug design, development and therapy
Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury.
Cureus
Tirzepatide data: safety always comes first!
Expert opinion on drug safety
The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions.
Journal of the American Association of Nurse Practitioners
Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists.
Vision (Basel, Switzerland)
Functional Performance of Silk Nanoparticles for Oral Drug Delivery.
ACS applied materials & interfaces
Trending on X
Everyone says peptides cause cancer. I pulled the studies. Here's what they actually show. 06:25 BPC-157 08:40 DSIP 09:54 Epitalon 12:15 GHK-Cu 14:45 KPV 16:03 LL-37 18:41 MOTS-c 20:00 Retatrutide 21:19 Semaglutide 22:24 SS-31 24:13 Thymosin Alpha-1 25:47 Tirzepatide https://t.co/2RBkMubEQP
Popular obesity medications significantly lower overall cancer risk, study finds. The breakthrough class of obesity medications, including GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP receptor agonists like tirzepatide, continue to make waves in modern medicine. https://t.co/Bul3Icqy4F
RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…
RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…
RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…
RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…
RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…
What 2026 research-chem buyers actually order — top 10 by share of all in-scope COAs in our corpus over the last 60 days: Retatrutide — 10.4% Tirzepatide — 8.5% BPC-157 — 7.8% GHK-Cu — 4.8% Tesamorelin — 4.4% MOTS-C — 4.1% Ipamorelin — 3.8% NAD+ — 3.2% Semaglutide — 3.1% TB-500
Provider Spotlight
Ivim Health
Telehealth platform offering peptide therapy and GLP-1 weight management with clinical oversight.